Based on a post hoc, pooled analysis of BOREAS and NOTUS, COPD exacerbations leading to hospital visitsb reduced by 38% in patients on DUPIXENT + triple therapy vs placebo + triple therapy, 0.16 for placebo (0.12-0.22) vs. 0.10 for DUPIXENT (0.07-0.14) (N=1874; OR 0.621; 95% CI: 0.427, 0.901) adjusted annualized rate of exacerbations leading to hospital visits.9,c
Results are descriptive. Definitive conclusions cannot be made.
bHospital visits is hospitalization or emergency department visits of any duration.
cBased on a post hoc analysis of BOREAS and NOTUS; phase 3, randomized, double-blind, placebo-controlled trials. Adjusted annualized rate of severe exacerbations and/or ED visits of patients ages 40 to 85 years with COPD, moderate-to severe airflow limitation, and type 2 inflammation (screening blood eosinophils ≥300 cells/μL) on LABA/LAMA/ICS. Patients received add-on dupilumab 300 mg or matching placebo Q2W for up to 52 weeks. Severe exacerbations and/or ED visits defined as exacerbations requiring hospitalization or an emergency department visit of any duration.
COPD, chronic obstructive pulmonary disease; ED, emergency department; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; OR, odds ratio; Q2W, once every 2 weeks.